ANI Pharmaceuticals, Inc.
Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
About
CEO
Mr. Nikhil Lalwani
Employees
642
Instrument type
Common Stock
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
MIC code
XNMS
Address
210 Main Street West, Baudette, MN 56623, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 8, 2025 | — | — | — | — |
| Feb 26, 2025 | 1.41 | — | — | — |
| Nov 8, 2024 | 1.09 | 1.34 | 0.25 | 22.94% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 4 |
| Average estimate | — | 0.14 | — | 1.93 |
| Low estimate | — | 0.02 | — | 0.96 |
| High estimate | — | 0.34 | — | 2.74 |
| Last year EPS | — | 0.82 | — | -0.28 |
[stock_revenue_estimate]
Growth estimates
Current qtr
43.500%
Next qtr. (Mar 2025)
-9.590%
Current year
6.300%
Next year (Dec 2025)
11.020%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 486.82M | 316.39M | 216.14M | 208.48M | 206.55M |
| Cost of revenue | 181.51M | 138.79M | 100.61M | 87.16M | 63.15M |
| Gross profit | 305.30M | 177.60M | 115.53M | 121.32M | 143.39M |
| Operating expense | |||||
| Research & development | 34.29M | 22.32M | 11.37M | 16.00M | 19.81M |
| Selling general and admin | 161.70M | 124.04M | 84.29M | 64.99M | 55.84M |
| Other operating expenses | — | — | 780,000 | 11.26M | 6.71M |
| Operating income | 49.53M | -25.73M | -28.17M | -15.57M | 16.43M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 26.94M | 28.05M | 11.92M | 9.45M | 12.97M |
| Other income expense | -2.72M | -8.88M | -15.97M | -940,000 | -303,000 |
| Pretax income | 19.87M | -62.67M | -56.06M | -25.96M | 3.16M |
| Tax provision | 1.09M | -14.77M | -13.46M | -3.41M | -2.94M |
| Net income | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M |
| Basic EPS | 0.86 | -3.05 | -3.40 | -1.88 | 0.51 |
| Diluted EPS | 0.85 | -3.05 | -3.40 | -1.88 | 0.50 |
| Basic average shares | 18.00M | 16.26M | 12.60M | 11.96M | 11.84M |
| Diluted average shares | 18.00M | 16.26M | 12.60M | 11.96M | 11.84M |
| EBITDA | 109.16M | 34.59M | 14.74M | 28.57M | 60.81M |
| Net income from continuing op. | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | 97,000 |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 904.42M | 760.09M | 771.60M | 461.19M | 456.79M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 221.12M | 48.23M | 100.30M | 7.86M | 62.33M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 162.08M | 165.44M | 128.53M | 95.79M | 72.13M |
| Other receivables | — | — | — | — | — |
| Inventory | 111.20M | 105.36M | 81.69M | 60.80M | 48.16M |
| Prepaid assets | — | 3.83M | 3.67M | — | 1.08M |
| Restricted cash | — | 5.01M | — | — | — |
| Assets held for sale | 8.02M | 8.02M | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 17.40M | 8.39M | 7.59M | 5.86M | 4.00M |
| Non current assets | |||||
| Properties | — | — | — | — | — |
| Land and improvements | 1.55M | 1.55M | 5.95M | 4.67M | 4.57M |
| Machinery furniture equipment | 50.41M | 53.15M | 46.77M | 39.11M | 34.98M |
| Construction in progress | 7.69M | 4.60M | 2.94M | 3.39M | 3.50M |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -32.94M | -32.71M | -22.96M | -17.53M | -12.77M |
| Goodwill | 265.45M | 308.08M | 349.90M | 195.67M | 187.55M |
| Investment properties | — | — | — | — | — |
| Financial assets | 12.07M | 11.36M | — | — | — |
| Intangible assets | 209.01M | 251.64M | 294.12M | 188.51M | 180.39M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 90.71M | 92.72M | 75.14M | 57.51M | 44.58M |
| Total liabilities | 446.82M | 421.55M | 412.86M | 265.49M | 244.00M |
| Current liabilities | |||||
| Accounts payable | 36.68M | 29.31M | 22.97M | 11.26M | 14.61M |
| Accrued expenses | 34.05M | 25.57M | 19.37M | 16.69M | 16.35M |
| Short term debt | 850,000 | 850,000 | 850,000 | 13.24M | 9.94M |
| Deferred revenue | — | — | 87,000 | 80,000 | 451,000 |
| Tax payable | 8.16M | — | — | 3.91M | — |
| Pensions | 23.79M | 10.31M | 8.52M | 6.23M | 3.74M |
| Other current liabilities | 12.27M | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 284.82M | 285.67M | 286.52M | 172.44M | 175.81M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | 7.80M | 14.48M | 6.51M |
| Other non current liabilities | 16.53M | 36.44M | 38.80M | — | 6.51M |
| Shareholders equity | |||||
| Common stock | 2,000 | 1,000 | 1,000 | 1,000 | 1,000 |
| Retained earnings | -80.13M | -97.29M | -47.77M | -4.97M | 17.58M |
| Other shareholders equity | 8.86M | 12.17M | -3.06M | -11.44M | -4.87M |
| Total shareholders equity | 457.60M | 338.54M | 358.74M | 195.70M | 212.79M |
| Additional paid in capital | 514.10M | 403.90M | 387.84M | 214.35M | 200.80M |
| Treasury stock | 10.08M | 5.09M | 3.14M | 2.25M | 723,000 |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||
| Net Income | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M | 15.49M | -1.08M | 3.93M | 15.38M | 28.75M | 301,000 | -27.72M | -51.61M | -46.20M | -47.53M | -17.43M | -7.58M | 2.79M | -9.65M | -12.02M | -5.96M | -3.81M | -2.61M | -3.44M | -1.41M | -2.66M |
| Depreciation | 59.79M | 59.65M | 47.25M | 44.64M | 44.61M | 33.74M | 27.93M | 22.34M | 6.90M | 3.88M | 1.11M | 258,946 | 148,240 | 167,986 | 137,280 | 43,137 | 89,824 | 117,781 | 100,938 | 101,943 | 92,927 | 92,099 | 110,560 | 122,790 | 90,965 | 139,769 |
| Deferred Taxes | -11.74M | -15.25M | -16.75M | -13.21M | -9.13M | -5.18M | 3.56M | -8.91M | -1.88M | -14.46M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 20.65M | 14.60M | 10.49M | 12.94M | 9.22M | 6.78M | 6.09M | 6.07M | 3.86M | 3.42M | 4.45M | 725,625 | 1.18M | 992,757 | 1.25M | 1.10M | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 6.62M | 9.17M | 3.01M | 5.63M | 9.35M | 9.80M | 7.67M | 7.28M | 6.83M | 559,000 | 217,000 | 4.33M | 23,427 | 1.81M | 29.28M | 104,284 | 604,166 | 1.08M | 750,000 | -1 | — | — | — | — | — | 129,931 |
| Accounts Receivable | 3.36M | -36.91M | -5.55M | -23.66M | -7.29M | -4.74M | -12.89M | -23.96M | -4.64M | -4.78M | -7.08M | — | — | 64,645 | 285,838 | -215,209 | 10.50M | -10.51M | — | — | — | — | — | — | — | — |
| Accounts Payable | 7.55M | 5.04M | 10.17M | -2.29M | 5.04M | 3.47M | 3,000 | 1.08M | -1.03M | 225,000 | -565,000 | -4.42M | 134,103 | 3.14M | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -9.56M | -26.03M | 9.73M | 7.61M | -3.62M | 3.90M | 7.87M | 1.17M | -4.83M | -1.61M | -3.56M | — | — | — | — | -9,091 | -3.23M | 2.29M | 200,795 | -14,115 | 302,625 | -718,079 | 433,319 | -30,347 | -86,045 | — |
| Operating Cash Flow | 95.45M | -37.63M | 15.74M | 9.10M | 54.27M | 63.26M | 39.15M | 9.00M | 20.60M | 15.98M | -5.13M | -26.82M | -50.13M | -40.02M | -16.57M | -16.40M | 371,902 | -4.24M | -8.60M | -11.93M | -5.56M | -4.44M | -2.07M | -3.34M | -1.40M | -2.39M |
| Investing Activities | ||||||||||||||||||||||||||
| Capital Expenditures | -8.87M | -8.13M | 92,000 | -6.14M | -6.64M | -5.74M | -10.37M | -4.57M | -2.18M | -1.12M | -191,000 | -611,193 | -719,925 | -60,366 | -165,724 | -651,116 | -29,428 | -39,255 | -67,416 | -103,204 | -8,865 | -38,992 | -86,735 | -43,238 | -4,219 | -124,984 |
| Net Intangibles | -9.64M | -7.58M | -21.08M | -62.19M | -20.91M | -5.17M | -97.62M | -144.49M | -30.50M | -34.63M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -33,000 | -84.49M | — | — | -16.47M | — | — | — | — | 18.20M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — | -7,955 | — | — | — | — | -11.21M | -8.01M | -392,375 | -16.10M | — | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.03M | 11.98M | 981 | 13.00M | 7.70M | — | — | — | — | — | — | — |
| Investing Cash Flow | -8.87M | -8.16M | -84.40M | -6.14M | -6.64M | -22.21M | -10.37M | -9.57M | -2.18M | -1.12M | 20.27M | -619,148 | -719,925 | -60,366 | 2.86M | 11.33M | -11.24M | 4.96M | 7.24M | -16.20M | -8,865 | -38,992 | -86,735 | -43,238 | -4,219 | -124,984 |
| Financing Activities | ||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | 24.00M | 15.00M | 118.00M | — | 75.00M | — | — | 138.24M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.26M |
| Long-Term Debt Payments | -3.00M | -3.00M | -211.01M | -15.53M | -121.46M | -28.94M | — | — | — | — | -4.07M | — | -1.23M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -12.50M | — | -19.38M | — | — | -1.20M | -2.74M | 323,000 | 360,000 | -14.84M | — | — | — | — | 22.32M | 319,377 | — | — | — | — | — | — | — | — | — | -1,875 |
| Financing Cash Flow | 58.44M | -6.58M | 173.14M | 5.44M | -4.49M | -30.79M | 72.00M | 201,000 | 247,000 | 170.08M | -8.56M | 3.26M | 67.60M | 48.45M | 33.67M | 638,754 | 18.49M | 7.38M | 197,768 | 18.68M | 9.78M | 4.38M | 3.80M | 30,033 | 4.23M | 4.26M |
| Other Cash Details | ||||||||||||||||||||||||||
| End Cash Position | 221.12M | 53.23M | 105.30M | 12.87M | 67.36M | 48.03M | 36.15M | 32.37M | 154.68M | 169.04M | 11.11M | 34.79M | 57.23M | 38.16M | 29.86M | 11.76M | 15.65M | 7.65M | 310,643 | 1.17M | 9.13M | 4.88M | 4.50M | 2.61M | 5.27M | 2.84M |
| Income Tax Paid | 1.23M | 288,000 | 10.37M | 4.98M | 10.03M | 6.40M | 17.79M | 9.54M | 13.26M | -147,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 31.43M | 21.48M | 9.71M | 6.93M | 6.09M | 6.29M | 3.76M | 4.08M | 4.15M | — | 250,000 | 313,435 | 688,000 | 688,000 | 248,388 | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 100.45M | -47.66M | -20.32M | -53.06M | 18.08M | 56.16M | -68.57M | -121.59M | -15.42M | -13.72M | -5.68M | -25.89M | -48.59M | -40.16M | -18.60M | -16.19M | 710,564 | -5.04M | -8.36M | -10.55M | -5.53M | -4.00M | -1.91M | -3.19M | -1.79M | -3.17M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | Nov 30, 2024 | 1,072,032 | 64.12M | 5.10% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 588,253 | 35.18M | 2.80% |
| Pacer Small Cap U.S. Cash Cows 100 ETF | Oct 31, 2024 | 555,702 | 33.24M | 2.64% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 510,202 | 30.52M | 2.43% |
| Delaware Ivy Small Cap Growth Fund | Sep 30, 2024 | 336,396 | 20.12M | 1.60% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 246,005 | 14.71M | 1.17% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 188,115 | 11.25M | 0.90% |
| Blair (William) Mutual Funds,Inc-Small Cap Value Fund | Nov 30, 2024 | 174,527 | 10.44M | 0.83% |
| iShares S&P Small-Cap 600 Growth ETF | Oct 31, 2024 | 160,951 | 9.63M | 0.77% |
| SPDR Portfolio S&P 600 Small Cap ETF | Nov 30, 2024 | 151,750 | 9.08M | 0.72% |
Article
Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jan 31, 2025
Article
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.
Jan 31, 2025
Article
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows:
Jan 28, 2025
